Objectives

After participating in this educational activity, attendees should be able to:
1| Describe the mechanism of action of CagriSema, including the complementary effects of semaglutide, a GLP-1 receptor agonist, and cagrilintide, an amylin receptor agonist

2| Evaluate the efficacy of CagriSema compared with semaglutide and cagrilintide, with emphasis on glycemic control and body-weight outcomes

Presenter(s): 
Alisha Ghoussein, PharmD
PGY1 Community-Based Pharmacy Resident
Baystate Health
 
NameRoleFinancial Relationship DisclosuresDiscussion of
Unlabeled/Unapproved Uses of
Drugs/Devices in Presentation?
Alisha Ghoussein, PharmDSpeaker/AuthorNo relevant relationships with ineligible companies to discloseNo
Session date: 
11/02/2026 - 2:00pm to 2:30pm EST
Location: 
Hybrid
United States
See map: Google Maps
Add to calendar: 
  • 0.50 ACPE Contact Hours
  • 0.50 ACPE Technician contact hours
Please login or register to take this course.